Medtronic Reports 7% Revenue Growth to $8.96 Billion in Q2 Fiscal 2026

Medtronic plc reported a notable increase in financial performance for the second quarter of fiscal year 2026, ending October 24, 2025. The company achieved net sales of $8.96 billion, a 7% increase from $8.40 billion in the same quarter of the previous year. For the first half of the fiscal year, net sales reached $17.54 billion, up 8% from $16.32 billion. Net income attributable to Medtronic for the quarter was $1.37 billion, or $1.07 per diluted share, compared to $1.27 billion, or $0.99 per diluted share, in the prior year. The increase in profitability was attributed to strong sales growth across various segments, particularly in Cardiac Rhythm & Heart Failure and Diabetes.

The company experienced significant growth in several product categories, with Cardiac Rhythm & Heart Failure sales rising 16% year-over-year to $1.83 billion, and Diabetes sales increasing 10% to $757 million. The overall growth was supported by favorable foreign currency fluctuations and adjustments related to the Italian payback accruals, which positively impacted net sales by $39 million in the first half of the fiscal year. Medtronic's operating profit for the quarter was $1.69 billion, reflecting a slight increase from $1.60 billion in the same period last year.

In terms of operational developments, Medtronic has announced its intention to separate its Diabetes business into a new independent, publicly traded company, with the separation expected to be completed within 18 months. The company also reported a restructuring charge of $10 million for the quarter, down from $30 million in the same quarter last year, indicating a reduction in costs associated with employee terminations and facility-related expenses. The total employee headcount remained stable at approximately 100,000.

Geographically, Medtronic's U.S. sales for the quarter were $4.52 billion, a 5% increase from $4.30 billion, while international sales rose 8% to $4.45 billion. The company continues to focus on expanding its market share in emerging markets and enhancing product adoption rates, particularly in the cardiovascular and diabetes segments. The company’s cash and cash equivalents stood at $1.28 billion as of October 24, 2025, down from $2.22 billion at the end of the previous fiscal year, reflecting increased investments and operational expenditures.

Looking ahead, Medtronic anticipates continued growth driven by product innovation and market expansion, despite potential challenges from macroeconomic factors such as inflation and global trade policies. The company remains committed to investing in research and development to enhance its product offerings and maintain its competitive edge in the healthcare technology sector.